- Shares of Cassava Sciences (SAVA -6.2%) are down in afternoon trading after announcing this morning it was starting a phase 3 trial of simufilam for Alzheimer's disease.
- Shares traded up in premarket trading.
- Although shares are up more than 738% year-to-date, the stock has had a roller coaster 2021. The company has faced criticism of the quality of its studies as well as a cold reception from investors to simufilam data presented at a medical conference this summer.
- Other companies with Alzheimer's candidates in the pipeline are also down on the day. This includes Anavex Life Sciences (AVXL -3.3%), Annovis Bio (ANVS -2.4%), and Alzamed Neuro (ALZN -7.6%).
- Last month, Cassava posted positive top-line data from an analysis of simufilam.
Cassava down after phase 3 simufilam announcement; other Alzheimer's names follow
Recommended For You
About SAVA Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
SAVA | - | - |
Cassava Sciences, Inc. |